Table 1.
Participants characteristics.
| Group | Negative | Vaccinated (2 doses) | Vaccinated (3 doses) | Convalescent | Hybrid immunity (1 or 2 doses) | Hybrid immunity (3 doses) |
|---|---|---|---|---|---|---|
| Group description | Non-vaccinated, never tested positive, NP negative, RBD negative | Never tested positive, anti-NP negative RBD positive | Never tested positive, NP negative, anti-RBD positive | Non-vaccinated, tested positive, NP positive, RBD positive | Infection after 1 or 2 doses of vaccine, NP positive, RBD positive | Infection after 3 doses of vaccine, NP positive, RBD positive |
| Number of patients | 11 | 29 | 25 | 21 | 31 | 26 |
| Age: median (range) | 28.5 (24–46) | 33 (24–59) | 37.5 (24–76) | 32 (23–64) | 39 (25–59) | 37.5 (23–55) |
| Sex: females (%) | 8 (72.7%) | 20 (69%) | 13 (52%) | 16 (76.2%) | 16 (51.6%) | 15 (57.7%) |
| Sex: males (%) | 3 (27.3%) | 9 (31%) | 12 (48%) | 5 (23.8%) | 15 (48.4%) | 11 (42.3%) |
| No of participants with >1 infection | na | na | na | 2 | 8 | 3 |
| Days since last immune response (DLIR), days, median (IQR) | na | 176 (159.3–210.5) | 70 (49–123) | 68 (37.25–376.75) | 44 (29–54) | 47.5 (37.75–58.25) |
| Statistical differences of means for DLIR between the groups (determined by Kruskal–Wallis test) | ||||||
| Vaccinated (2 doses) | na | na | p < 0.001 | p = 0.021 | p < 0.001 | p < 0.001 |
| Vaccinated (3 doses) | na | na | >0.999 | p = 0.1752 | p = 0.678 | |
| Convalescent | na | na | p = 0.049 | p = 0.211 | ||
| Hybrid Immunity (1 or 2 doses) | na | na | p > 0.999 | |||
| Hybrid Immunity (3 doses) | na | na | ||||
| Vaccinated (2 doses) | na | |||||
| No. of subjects with unknown date of infection | na | na | na | 3 | – | – |